As part of its CareCentered Contracting program, pharmacy benefit manager (PBM) Prime Therapeutics recently entered into an outcomes-based contract with Boehringer Ingelheim for Jardiance (empagliflozin), an oral type 2 diabetes medicine indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
As a PBM owned by 18 Blue Cross and Blue Shield plans, Prime is uniquely positioned to analyze both medical and pharmacy claims data to evaluate and manage total cost of care. Prime looks at members' experiences holistically and this CareCentered Contracting agreement will focus on the total cost of care for members taking Jardiance and comparing that to the total cost of care for patients taking other diabetic medications. In this manner, Prime can truly evaluate the combined cost of pharmacy and medical on select therapies and its impact on overall health costs for the members we serve.
"Because diabetes affects nearly 10 percent of the U.S. population, Prime actively works to find solutions that can improve our members' health outcomes and control the overall costs of diabetes," said Jonathan Gavras, M.D., chief medical officer at Prime. "Establishing a CareCentered Contracting agreement for Jardiance allows us to collect and analyze important data beyond pharmacy claims. These insights help drive the greatest value from the treatment."
Jardiance adds to Prime's portfolio of CareCentered Contracting agreements in the diabetes category and the comprehensive treatment of diabetes is an area of strategic focus for Prime.